Cargando…

Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches

Recurrent pregnancy loss (RPL) occurs in approximately 5% of women. Despite an abundance of evidence, the molecular mechanism of RPL’s pathology remains unclear. Here, we report the protective role of polo-like kinase 1 (PLK1) during RPL. We aimed to construct an RPL network utilizing GEO datasets a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramírez-Coronel, Andrés Alexis, Rostami, Amirabbas, Younus, Laith A., Arias Gonzáles, José Luis, Lafta, Methaq Hadi, Amin, Ali H., Saadoon, Mohammed Abdulkadhim, Salman, Hayder Mahmood, Bahrami, Abolfazl, Feilei, Rossa, Akhavan-Sigari, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045586/
https://www.ncbi.nlm.nih.gov/pubmed/36979858
http://dx.doi.org/10.3390/biomedicines11030879
_version_ 1784913640597487616
author Ramírez-Coronel, Andrés Alexis
Rostami, Amirabbas
Younus, Laith A.
Arias Gonzáles, José Luis
Lafta, Methaq Hadi
Amin, Ali H.
Saadoon, Mohammed Abdulkadhim
Salman, Hayder Mahmood
Bahrami, Abolfazl
Feilei, Rossa
Akhavan-Sigari, Reza
author_facet Ramírez-Coronel, Andrés Alexis
Rostami, Amirabbas
Younus, Laith A.
Arias Gonzáles, José Luis
Lafta, Methaq Hadi
Amin, Ali H.
Saadoon, Mohammed Abdulkadhim
Salman, Hayder Mahmood
Bahrami, Abolfazl
Feilei, Rossa
Akhavan-Sigari, Reza
author_sort Ramírez-Coronel, Andrés Alexis
collection PubMed
description Recurrent pregnancy loss (RPL) occurs in approximately 5% of women. Despite an abundance of evidence, the molecular mechanism of RPL’s pathology remains unclear. Here, we report the protective role of polo-like kinase 1 (PLK1) during RPL. We aimed to construct an RPL network utilizing GEO datasets and identified hub high-traffic genes. We also investigated whether the expressions of PLK1 were altered in the chorionic villi collected from women with RPL compared to those from healthy early pregnant women. Gene expression differences were evaluated using both pathway and gene ontology (GO) analyses. The identified genes were validated using in vivo and in vitro models. Mice with PLK1-overexpression and PLK1-knockdown in vitro models were produced by transfecting certain plasmids and si-RNA, respectively. The apoptosis in the chorionic villi, mitochondrial function, and NF-κB signaling activity was evaluated. To suppress the activation of PLK1, the PLK1 inhibitor BI2536 was administered. The HTR-8/SVneo and JEG-3 cell lines were chosen to establish an RPL model in vitro. The NF-κB signaling, Foxo signaling, PI3K/AKT, and endometrial cancer signaling pathways were identified via the RPL regulatory network. The following genes were identified: PLK1 as hub high-traffic gene and MMP2, MMP9, BAX, MFN1, MFN2, FOXO1, OPA1, COX15, BCL2, DRP1, FIS1, TRAF2, and TOP2A. Clinical samples were examined, and the results demonstrated that RPL patients had tissues with decreased PLK1 expression in comparison to women with normal pregnancies (p < 0.01). In vitro, PLK1 knockdown induced the NF-κB signaling pathway and apoptosis activation while decreasing cell invasion, migration, and proliferation (p < 0.05). Furthermore, the in vivo model proved that cell mitochondrial function and chorionic villi development are both hampered by PLK1 suppression. Our findings revealed that the PLK1/TRAF2/NF-κB axis plays a crucial role in RPL-induced chorionic villi dysfunction by regulating mitochondrial dynamics and apoptosis and might be a potential therapeutic target in the clinic.
format Online
Article
Text
id pubmed-10045586
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100455862023-03-29 Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches Ramírez-Coronel, Andrés Alexis Rostami, Amirabbas Younus, Laith A. Arias Gonzáles, José Luis Lafta, Methaq Hadi Amin, Ali H. Saadoon, Mohammed Abdulkadhim Salman, Hayder Mahmood Bahrami, Abolfazl Feilei, Rossa Akhavan-Sigari, Reza Biomedicines Article Recurrent pregnancy loss (RPL) occurs in approximately 5% of women. Despite an abundance of evidence, the molecular mechanism of RPL’s pathology remains unclear. Here, we report the protective role of polo-like kinase 1 (PLK1) during RPL. We aimed to construct an RPL network utilizing GEO datasets and identified hub high-traffic genes. We also investigated whether the expressions of PLK1 were altered in the chorionic villi collected from women with RPL compared to those from healthy early pregnant women. Gene expression differences were evaluated using both pathway and gene ontology (GO) analyses. The identified genes were validated using in vivo and in vitro models. Mice with PLK1-overexpression and PLK1-knockdown in vitro models were produced by transfecting certain plasmids and si-RNA, respectively. The apoptosis in the chorionic villi, mitochondrial function, and NF-κB signaling activity was evaluated. To suppress the activation of PLK1, the PLK1 inhibitor BI2536 was administered. The HTR-8/SVneo and JEG-3 cell lines were chosen to establish an RPL model in vitro. The NF-κB signaling, Foxo signaling, PI3K/AKT, and endometrial cancer signaling pathways were identified via the RPL regulatory network. The following genes were identified: PLK1 as hub high-traffic gene and MMP2, MMP9, BAX, MFN1, MFN2, FOXO1, OPA1, COX15, BCL2, DRP1, FIS1, TRAF2, and TOP2A. Clinical samples were examined, and the results demonstrated that RPL patients had tissues with decreased PLK1 expression in comparison to women with normal pregnancies (p < 0.01). In vitro, PLK1 knockdown induced the NF-κB signaling pathway and apoptosis activation while decreasing cell invasion, migration, and proliferation (p < 0.05). Furthermore, the in vivo model proved that cell mitochondrial function and chorionic villi development are both hampered by PLK1 suppression. Our findings revealed that the PLK1/TRAF2/NF-κB axis plays a crucial role in RPL-induced chorionic villi dysfunction by regulating mitochondrial dynamics and apoptosis and might be a potential therapeutic target in the clinic. MDPI 2023-03-13 /pmc/articles/PMC10045586/ /pubmed/36979858 http://dx.doi.org/10.3390/biomedicines11030879 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ramírez-Coronel, Andrés Alexis
Rostami, Amirabbas
Younus, Laith A.
Arias Gonzáles, José Luis
Lafta, Methaq Hadi
Amin, Ali H.
Saadoon, Mohammed Abdulkadhim
Salman, Hayder Mahmood
Bahrami, Abolfazl
Feilei, Rossa
Akhavan-Sigari, Reza
Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches
title Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches
title_full Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches
title_fullStr Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches
title_full_unstemmed Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches
title_short Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches
title_sort designing effective multi-target drugs and identifying biomarkers in recurrent pregnancy loss (rpl) using in vivo, in vitro, and in silico approaches
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10045586/
https://www.ncbi.nlm.nih.gov/pubmed/36979858
http://dx.doi.org/10.3390/biomedicines11030879
work_keys_str_mv AT ramirezcoronelandresalexis designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches
AT rostamiamirabbas designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches
AT younuslaitha designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches
AT ariasgonzalesjoseluis designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches
AT laftamethaqhadi designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches
AT aminalih designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches
AT saadoonmohammedabdulkadhim designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches
AT salmanhaydermahmood designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches
AT bahramiabolfazl designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches
AT feileirossa designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches
AT akhavansigarireza designingeffectivemultitargetdrugsandidentifyingbiomarkersinrecurrentpregnancylossrplusinginvivoinvitroandinsilicoapproaches